Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMS-D017 SAD and MAD in Healthy Participants
NCT07462780Phase 1Recruiting
- Sponsor
- Shenzhen Kangzhe Biotechnology
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMS-D017 in paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated kidney disease (4 arms), sponsored by Shenzhen Kangzhe Biotechnology. Primary endpoint: Adverse Events at 23 days. Started Mar 2026; status: recruiting.
02
Drugs
CMS-D017
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)complement-mediated kidney disease
Beyond the preview
Go deeper on NCT07462780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462780.